Zacks Investment Research
26 Mar 2026, 14:06 UTC · 26w ago
Verdict
Headline leans bullish. We score PACB +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Basecamp Research has selected PacBio's HiFi sequencing technology and Revio system for the Trillion Gene Atlas initiative.
More positive than 79% of claims this week
The Trillion Gene Atlas project aims to generate nearly 100,000 deeply sequenced samples from over 31 countries.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company announced a strategic collaboration with Basecamp Research that strengthens long-term growth and creates recurring demand for its sequencing technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+16.5%
Price agrees with the score
$1.62 vs $1.39 close before publication (Mar 25) · not market-adjusted
PACB chart →
